Free Trial

Praxis Precision Medicines (PRAX) Competitors

Praxis Precision Medicines logo
$46.68 -0.58 (-1.23%)
As of 07/7/2025 04:00 PM Eastern

PRAX vs. RNA, RARE, PTGX, AAPG, SRRK, MLTX, MTSR, VKTX, KYMR, and MOR

Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.

Praxis Precision Medicines vs. Its Competitors

Praxis Precision Medicines (NASDAQ:PRAX) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Praxis Precision Medicines has a net margin of -2,137.48% compared to Avidity Biosciences' net margin of -4,136.00%. Avidity Biosciences' return on equity of -26.96% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision Medicines-2,137.48% -50.42% -46.74%
Avidity Biosciences -4,136.00%-26.96%-24.57%

67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 2 articles in the media. Avidity Biosciences' average media sentiment score of 0.92 beat Praxis Precision Medicines' score of 0.42 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avidity Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Praxis Precision Medicines presently has a consensus target price of $92.11, suggesting a potential upside of 97.32%. Avidity Biosciences has a consensus target price of $65.59, suggesting a potential upside of 127.74%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Avidity Biosciences
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06

Praxis Precision Medicines has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision Medicines$8.55M111.21-$182.82M-$10.72-4.35
Avidity Biosciences$10.90M318.44-$322.30M-$3.00-9.60

Praxis Precision Medicines has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Summary

Avidity Biosciences beats Praxis Precision Medicines on 11 of the 16 factors compared between the two stocks.

Get Praxis Precision Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRAX vs. The Competition

MetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$962.64M$2.91B$5.52B$9.02B
Dividend YieldN/A2.44%5.24%4.07%
P/E Ratio-4.3520.4427.2220.04
Price / Sales111.21181.20380.3292.37
Price / CashN/A41.7026.2128.59
Price / Book1.957.397.945.55
Net Income-$182.82M-$55.04M$3.17B$248.49M
7 Day Performance8.13%2.51%1.81%4.87%
1 Month Performance4.76%-0.21%1.28%6.63%
1 Year Performance10.15%3.41%33.57%20.38%

Praxis Precision Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRAX
Praxis Precision Medicines
2.9217 of 5 stars
$46.68
-1.2%
$92.11
+97.3%
+15.8%$962.64M$8.55M-4.35110
RNA
Avidity Biosciences
2.4611 of 5 stars
$28.40
-2.2%
$65.59
+130.9%
-26.2%$3.50B$10.90M-9.47190
RARE
Ultragenyx Pharmaceutical
3.935 of 5 stars
$36.36
-0.4%
$87.00
+139.3%
-3.1%$3.45B$560.23M-6.181,294
PTGX
Protagonist Therapeutics
2.085 of 5 stars
$55.27
-0.8%
$66.10
+19.6%
+47.9%$3.45B$434.43M73.69120
AAPG
Ascentage Pharma Group International
N/A$39.38
-0.6%
N/AN/A$3.45B$134.35M0.00600
SRRK
Scholar Rock
3.3172 of 5 stars
$35.42
-1.1%
$42.67
+20.5%
+358.4%$3.40B$33.19M-14.00140
MLTX
MoonLake Immunotherapeutics
1.9777 of 5 stars
$47.20
-0.7%
$74.50
+57.8%
+13.0%$3.04BN/A-20.522Positive News
MTSR
Metsera
N/A$28.45
-0.5%
$55.00
+93.3%
N/A$3.00BN/A0.0081
VKTX
Viking Therapeutics
3.8404 of 5 stars
$26.50
-0.1%
$87.15
+228.9%
-46.3%$2.98BN/A-23.0420
KYMR
Kymera Therapeutics
3.3151 of 5 stars
$43.64
-1.1%
$59.61
+36.6%
+44.8%$2.87B$47.07M-14.08170
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730

Related Companies and Tools


This page (NASDAQ:PRAX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners